Leap Therapeutics (LPTX) Stock Price, News & Analysis

Company Overview

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Key Stats

• Today's Range: $0.27 to $0.30
• 50-Day Range: $0.24 to $0.39
• 52-Week Range: $0.22 to $4.79
• Volume: 1.03 million shs
• Average Volume: 2.08 million shs
• Market Capitalization: $12.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.38
• Consensus Rating: Hold

Leap Therapeutics Stock Analysis - MarketRank™

Leap Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 626th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Leap Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Leap Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Leap Therapeutics are expected to grow in the coming year, from ($1.84) to ($1.36) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Leap Therapeutics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Leap Therapeutics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Leap Therapeutics has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.98% of the float of Leap Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Leap Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Leap Therapeutics has recently decreased by 25.37%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Leap Therapeutics does not currently pay a dividend.

Dividend Growth

Leap Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.98% of the float of Leap Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Leap Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Leap Therapeutics has recently decreased by 25.37%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Leap Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.50% of the stock of Leap Therapeutics is held by insiders.

Percentage Held by Institutions

Only 30.46% of the stock of Leap Therapeutics is held by institutions.

LPTX Stock Analysis - Frequently Asked Questions

How have LPTX shares performed this year?

Leap Therapeutics' stock was trading at $2.88 on January 1st, 2025. Since then, LPTX stock has decreased by 89.7% and is now trading at $0.2978.

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics, Inc. (NASDAQ:LPTX) announced its quarterly earnings data on Thursday, August, 14th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $0.11.

When did Leap Therapeutics' stock split?

Leap Therapeutics's stock reverse split on the morning of Wednesday, June 21st 2023.The 1-10 reverse split was announced on Wednesday, June 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Leap Therapeutics' major shareholders?

Leap Therapeutics' top institutional investors include Simplify Asset Management Inc. (2.07%), Key Client Fiduciary Advisors LLC (0.83%), Group One Trading LLC and Simplex Trading LLC.
View institutional ownership trends.

How do I buy shares of Leap Therapeutics?

Shares of LPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Leap Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Leap Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Meta Platforms (META), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Vaxart (VXRT) and OPKO Health (OPK).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 8/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LPTX
• CIK: 1509745
• Web: www.leaptx.com
• Phone: (617) 714-0360
• Fax: N/A
• Employees: 40
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Leap Therapeutics: $3.38
• High Price Target: $5.50
• Low Price Target: $1.25
• Potential Upside/Downside: +1,033.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$67.56 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -237.65%
• Return on Assets: -155.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.34
• Quick Ratio: 2.41

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.14 per share
• Price / Book: 2.13

Miscellaneous

• Outstanding Shares: 41,440,000
• Free Float: 38,332,000
• Market Cap: $12.34 million
• Optionable: Optionable
• Beta: -0.27